What Doctors and Researchers Say About Vaccine Safety

Dozens of credentialled physicians, researchers, and investigators have documented specific concerns about vaccine safety that do not appear in mainstream health communications. Their findings cover ingredient toxicology, trial design flaws, suppressed regulatory data, and the legal framework that removes manufacturer liability for vaccine injury. This page draws on their testimony and published research.

• Many vaccines contain aluminium adjuvants at doses that exceed the EPA's own safety limits for parenteral exposure in newborns.
• A CDC senior scientist disclosed that statistically significant data linking the MMR vaccine to autism in African-American boys was removed from a published study before submission.
• The Gardasil HPV vaccine trials used an aluminium-containing solution as the placebo rather than an inert substance, making it impossible to detect aluminium-related adverse events in the trial data.
• Vaccine manufacturers have held complete legal immunity from injury lawsuits since 1986. A 2011 Supreme Court ruling confirmed vaccines are "unavoidably unsafe" as a legal category.
• Natural infection with childhood diseases confers broader and longer-lasting immunity than vaccination and has historically correlated with lower rates of chronic disease in adulthood.
• The VAERS adverse event reporting system captures an estimated 1-10% of actual vaccine adverse events. Healthcare providers are not required by law to report reactions.

What vaccine ingredients actually do in the body

Vaccines contain active ingredients (antigens) and a range of additional substances including adjuvants, preservatives, stabilisers, and residual manufacturing compounds. Understanding what these substances do matters because they are injected directly into the bloodstream, bypassing the digestive and mucosal immune systems that normally filter and process foreign material.

Aluminium salts are the most widely used adjuvants in vaccines for hepatitis A, hepatitis B, DTaP, Tdap, HPV, and pneumococcal vaccines. Adjuvants work by triggering localised inflammation that recruits a stronger immune response to the antigen. The problem identified by researchers including Dr Christopher Shaw and Dr Lucija Tomljenovic is that injected aluminium is not handled the same way as ingested aluminium. Injected aluminium can be transported by immune cells across the blood-brain barrier and has been found in brain tissue in animal studies. The FDA sets a maximum parenteral aluminium dose of 25 micrograms per kilogram of body weight per day. Multiple independent researchers have calculated that the aluminium dose in the newborn hepatitis B vaccine alone substantially exceeds this limit for an average newborn.

Thimerosal, a preservative containing approximately 50% ethylmercury by weight, was announced as removed from childhood vaccines in 2003. The removal applied to three specific vaccines. In the same year, the CDC added flu vaccines to the recommended schedule for pregnant women and young children. Most flu vaccines at that time contained thimerosal at higher doses than the three vaccines from which it had been removed. The net result for many children was no reduction in cumulative mercury exposure, and for the first time, foetal exposure in utero.

Formaldehyde is used in vaccine manufacturing to inactivate viruses and bacterial toxins and appears as a residual in several formulations. The WHO classifies formaldehyde as a known human carcinogen. Researchers note that the body produces and metabolises small amounts of formaldehyde naturally, but that injected residual formaldehyde bypasses normal metabolic processing pathways.

The safety testing gap and what it means

Pre-market safety testing for vaccines differs from the testing applied to other pharmaceutical products in several important ways. Most vaccine trials do not use a true inert placebo. They use either a different vaccine or an aluminium-containing solution as the comparison group. This design makes it impossible to identify adverse events that are caused by the adjuvant rather than the antigen, because the control group is exposed to the same adjuvant.

Dr Toni Bark, a physician and former medical director of a paediatric emergency department, reviewed the Gardasil Phase 3 trial data and found that the placebo used was not a saline solution but a solution containing the same aluminium adjuvant used in the vaccine. The published adverse event rates in both the vaccine and placebo groups were therefore similar. She argued this design cannot support claims that Gardasil is safe, because it cannot distinguish aluminium-related effects from vaccine-specific effects.

Long-term studies of vaccine safety, meaning studies following recipients for years or decades, are rare. The clinical trials supporting vaccine approval typically follow participants for days to weeks after administration. Chronic conditions that develop over months or years after vaccination, including autoimmune conditions, neurological disorders, and gut dysfunction, fall outside the observation window of pre-approval trials.

No studies have been conducted on the safety of administering multiple vaccines simultaneously with multiple adjuvants and multiple antigens. At the 2018 meeting of the CDC's Advisory Committee on Immunization Practices, a committee member was asked directly whether such studies existed. The response was: "We have no data to make a recommendation one way or the other." A colleague clarified that the standard practice of giving vaccines in different limbs simultaneously had never been tested for combinatory effects.

Suppressed findings and institutional pressure on researchers

Several researchers who published findings critical of specific vaccines or vaccine ingredients describe facing institutional and professional consequences that are disproportionate to any scientific rebuttal of their work.

Dr Andrew Wakefield published a 1998 case series in The Lancet describing gastrointestinal disease and developmental regression in twelve children whose parents associated the onset with MMR vaccination. The paper was retracted in 2010 and Wakefield lost his medical licence. Wakefield and his colleagues contend that the retraction followed a campaign coordinated by journalist Brian Deer, funded by a Sunday Times proprietor with substantial pharmaceutical holdings, and that the clinical findings themselves were never addressed on their scientific merits. The children described in the original paper received treatment for bowel disease that improved their symptoms.

Dr William Thompson, a senior CDC scientist, disclosed in 2014 that he and colleagues had identified a statistically significant association between MMR vaccination before 36 months and autism diagnosis in African-American boys. He stated that this finding was removed from the published version of the study by altering the study population criteria after the analysis had been completed. Thompson retained documents supporting his account and submitted them to a US congressman. The CDC has not formally investigated the allegation and the study has not been retracted.

Dr Judy Mikovits, a molecular virologist and 20-year veteran of the National Cancer Institute, co-authored research connecting a mouse retrovirus (XMRV) to chronic fatigue syndrome. Her findings were disputed, her lab was closed, and she was subsequently arrested on charges that were later dropped without conviction. Independent researchers including Dr Frank Ruscetti published corroborating findings. The question of retroviral contamination in biological manufacturing processes, which affects vaccines produced in cell lines, has not been resolved.

Dr Gary Goldman was contracted by the CDC to analyse post-licensure data on the chickenpox vaccine. His analysis found that suppressing chickenpox in children reduced the natural immune re-exposure that adults rely on for protection against shingles, and that shingles rates were rising in adults as a direct consequence. The CDC did not act on his findings. His contract was not renewed.

The legal and financial structure of vaccine manufacturing

The National Childhood Vaccine Injury Act of 1986 removed the right to sue vaccine manufacturers in civil court for vaccine injuries or deaths. All claims must go through the National Vaccine Injury Compensation Program, a federal no-fault system funded by a tax on each vaccine sold. Since 1986, over 4.5 billion dollars has been paid out to families of vaccine-injured children and adults. The money does not come from manufacturers. It comes from the tax on vaccine sales, meaning vaccine consumers collectively fund the compensation system while manufacturers bear no financial consequence for injuries.

The 1986 Act also required the Department of Health and Human Services to conduct biennial safety reviews and report to Congress. Informed Consent Action Network submitted a Freedom of Information request for those reports in 2018. DHHS confirmed that no such reports had been produced in the 32 years since the Act was passed. The safety review requirement that was the public health justification for granting manufacturer immunity had never been met.

A 2011 Supreme Court decision in Bruesewitz versus Wyeth ruled that vaccines are "unavoidably unsafe" as a legal category, upholding the 1986 Act's manufacturer protections. This legal finding coexists with public health communications from the CDC describing vaccines as "very safe."

Natural immunity and what the historical data shows

Mortality graphs for measles, pertussis, diphtheria, and scarlet fever in the United States and United Kingdom show that deaths from these diseases had declined by 90% or more before vaccines for them were introduced. The graphs, compiled by Dr Suzanne Humphries and Roman Bystrianyk in their book Dissolving Illusions using official vital statistics data, suggest that improved sanitation, clean water, nutrition, and living conditions drove the reduction in mortality, not vaccination.

Natural infection with diseases such as measles, mumps, and chickenpox confers lifelong immunity. It also appears to provide broader protection. Research cited by multiple experts in this source suggests that children who recover from natural measles have lower rates of certain cancers and atopic conditions in adulthood compared to vaccinated children. The mechanism proposed is that natural infection trains the full innate and adaptive immune response, including the mucosal immune system, in ways that injection bypasses.

Homeoprophylaxis, the use of homeopathic preparations to stimulate disease-specific immunity, has been used in public health programmes in Cuba, India, and Brazil as an alternative to conventional vaccination. The evidence base is observational rather than randomised controlled trial data, but large-scale programme outcomes have been published in peer-reviewed journals. Researchers including Dr Isaac Golden have documented outcomes over multi-year follow-up periods.

Where these ideas come from

The ideas in this section of the knowledge base originate from the work of Ty Bollinger and Charlene Bollinger, specifically The Truth About Vaccines Documentary and Expert Interviews, produced and distributed by TTAV Global (2017). The Bollingers are investigative health journalists and documentary producers who have spent over a decade interviewing physicians, researchers, attorneys, and affected families on vaccine safety. The documentary series features testimony from more than 60 credentialled experts across immunology, toxicology, neurology, molecular biology, and public health. If you want to experience the original work in full, it is worth seeking out directly.

The knowledge base itself is an independent work. Every concept has been studied, rewritten from scratch, and restructured for use in a multi-source advisory system. Nothing from the original has been reproduced. The knowledge has been transformed, not copied. The source is named clearly because the ideas deserve proper credit, and because the original work stands on its own merits.